FDA Approves Cablivi for Rare Blood-Clotting Disorder

WEDNESDAY, Feb. 6, 2019 — Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP). “Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of…